US8209024B2 - Method and apparatus for treating ischemic diseases - Google Patents
Method and apparatus for treating ischemic diseases Download PDFInfo
- Publication number
- US8209024B2 US8209024B2 US12/523,990 US52399008A US8209024B2 US 8209024 B2 US8209024 B2 US 8209024B2 US 52399008 A US52399008 A US 52399008A US 8209024 B2 US8209024 B2 US 8209024B2
- Authority
- US
- United States
- Prior art keywords
- oxygen
- cathode
- anode
- biological fluid
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
- 238000000034 method Methods 0.000 title claims description 42
- 208000023589 ischemic disease Diseases 0.000 title abstract description 5
- 239000001301 oxygen Substances 0.000 claims abstract description 117
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 117
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 116
- 238000005868 electrolysis reaction Methods 0.000 claims abstract description 43
- 210000004127 vitreous body Anatomy 0.000 claims abstract description 25
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 38
- 230000015572 biosynthetic process Effects 0.000 claims description 38
- 239000000126 substance Substances 0.000 claims description 33
- 239000013060 biological fluid Substances 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- 230000000302 ischemic effect Effects 0.000 claims description 27
- 238000007254 oxidation reaction Methods 0.000 claims description 18
- 230000003647 oxidation Effects 0.000 claims description 16
- 241000124008 Mammalia Species 0.000 claims description 7
- 230000002051 biphasic effect Effects 0.000 claims description 6
- 239000000460 chlorine Substances 0.000 abstract description 46
- 229910052801 chlorine Inorganic materials 0.000 abstract description 46
- 230000002207 retinal effect Effects 0.000 abstract description 20
- 238000011282 treatment Methods 0.000 abstract description 19
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract description 16
- 208000028867 ischemia Diseases 0.000 abstract description 12
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 208000005590 Choroidal Neovascularization Diseases 0.000 abstract description 5
- 206010060823 Choroidal neovascularisation Diseases 0.000 abstract description 5
- 230000002441 reversible effect Effects 0.000 abstract description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 54
- 210000001519 tissue Anatomy 0.000 description 42
- 238000004519 manufacturing process Methods 0.000 description 32
- 210000001525 retina Anatomy 0.000 description 25
- 238000006213 oxygenation reaction Methods 0.000 description 23
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 18
- 241000282472 Canis lupus familiaris Species 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 17
- 239000001257 hydrogen Substances 0.000 description 17
- 229910052739 hydrogen Inorganic materials 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 13
- 239000012530 fluid Substances 0.000 description 13
- -1 hydroxyl ions Chemical class 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 238000002347 injection Methods 0.000 description 13
- 241000283973 Oryctolagus cuniculus Species 0.000 description 12
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 12
- 238000012014 optical coherence tomography Methods 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 208000017442 Retinal disease Diseases 0.000 description 9
- 206010038923 Retinopathy Diseases 0.000 description 9
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 9
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 9
- 235000010323 ascorbic acid Nutrition 0.000 description 9
- 239000011668 ascorbic acid Substances 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 229910052751 metal Inorganic materials 0.000 description 8
- 239000002184 metal Substances 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 210000003462 vein Anatomy 0.000 description 8
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 7
- 239000003792 electrolyte Substances 0.000 description 7
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Inorganic materials Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 7
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 241000894007 species Species 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- 210000001742 aqueous humor Anatomy 0.000 description 6
- 230000005540 biological transmission Effects 0.000 description 6
- 238000013534 fluorescein angiography Methods 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 238000002513 implantation Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 230000036284 oxygen consumption Effects 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 229910052697 platinum Inorganic materials 0.000 description 6
- 230000001292 preischemic effect Effects 0.000 description 6
- 229960005070 ascorbic acid Drugs 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 4
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 4
- 206010038848 Retinal detachment Diseases 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 229940072107 ascorbate Drugs 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 229910001882 dioxygen Inorganic materials 0.000 description 4
- 229920002674 hyaluronan Polymers 0.000 description 4
- 229960003160 hyaluronic acid Drugs 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000003252 repetitive effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 102000016938 Catalase Human genes 0.000 description 3
- 108010053835 Catalase Proteins 0.000 description 3
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 3
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 3
- 201000010183 Papilledema Diseases 0.000 description 3
- 201000007527 Retinal artery occlusion Diseases 0.000 description 3
- 206010038886 Retinal oedema Diseases 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 230000004264 retinal detachment Effects 0.000 description 3
- 201000011195 retinal edema Diseases 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 241000282465 Canis Species 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000003570 air Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 238000003843 chloralkali process Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000000446 fuel Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000000053 physical method Methods 0.000 description 2
- 229920000052 poly(p-xylylene) Polymers 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 208000004644 retinal vein occlusion Diseases 0.000 description 2
- 210000001210 retinal vessel Anatomy 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000007727 signaling mechanism Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000007998 vessel formation Effects 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 238000000116 DAPI staining Methods 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000010455 autoregulation Effects 0.000 description 1
- 201000007917 background diabetic retinopathy Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000004452 decreased vision Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- UJKWLAZYSLJTKA-UHFFFAOYSA-N edma Chemical compound O1CCOC2=CC(CC(C)NC)=CC=C21 UJKWLAZYSLJTKA-UHFFFAOYSA-N 0.000 description 1
- 238000003487 electrochemical reaction Methods 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 230000005674 electromagnetic induction Effects 0.000 description 1
- 238000006056 electrooxidation reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 231100000171 higher toxicity Toxicity 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000010746 intraretinal hemorrhage Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004377 microelectronic Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- RECVMTHOQWMYFX-UHFFFAOYSA-N oxygen(1+) dihydride Chemical compound [OH2+] RECVMTHOQWMYFX-UHFFFAOYSA-N 0.000 description 1
- 230000001706 oxygenating effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000009290 primary effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000001846 repelling effect Effects 0.000 description 1
- 208000032253 retinal ischemia Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- XOLBLPGZBRYERU-UHFFFAOYSA-N tin dioxide Chemical compound O=[Sn]=O XOLBLPGZBRYERU-UHFFFAOYSA-N 0.000 description 1
- 229910001887 tin oxide Inorganic materials 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013042 tunel staining Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/205—Applying electric currents by contact electrodes continuous direct currents for promoting a biological process
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/326—Applying electric currents by contact electrodes alternating or intermittent currents for promoting growth of cells, e.g. bone cells
Definitions
- the present invention relates to methods and an apparatus for the treatment of ischemic diseases and more particularly to treatment of diabetic retinopathy and ischemia of other biological tissues.
- Diabetes is known to adversely affect the circulatory system of the retina. This usually occurs in several stages, two of which are background diabetic retinopathy and proliferative diabetic retinopathy.
- proliferative diabetic retinopathy In the proliferative stage of diabetic retinopathy, poor circulation in the retina causes it to become oxygen-deprived (causing ischemia of the retinal and choroidal tissues).
- oxygen-deprived causing ischemia of the retinal and choroidal tissues
- neovascularization occurs, wherein vessels develop in an attempt to maintain sufficient oxygen in the retina.
- the newly-formed vessels are delicate and hemorrhage easily, leaking blood into the vitreous, thereby causing decreased vision.
- subsequent vessel growth and scar tissue can cause retinal detachment and glaucoma.
- Choroidal neovascularization has also been attributed to choroidal ischemias (Choroidal Neovascularization Correlated With Choroidal. Ischemia, Ann-Pascale Guagnini, MD; Bernadette Snyers, MD; Alexandra Kozyreff, MD; Laurent Levecq, MD; Patrick De Potter, MD, PhD Arch Opthalmol . (2006) 124:1063). Choroidal neovascularization can occur in the setting of age-related macular degeneration and is the leading cause of blindness in the age group of 65 years and older in the western countries.
- U.S. Pat. No. 7,064,141 discloses a method for preventing, treating or inhibiting development of simple retinopathy and preproliferative retinopathy by use of a pharmaceutical composition having angiotensin II antagonistic activity.
- U.S. Pat. No. 6,943,145 discloses compounds and a method for the prevention and treatment of diabetic retinopathy.
- U.S. Pat. No. 6,916,824 discloses methods of treating cataracts and diabetic retinopathy with tricyclic pyrones.
- 6,156,785 discloses a method for increasing oxygen tension in the optic nerve and retina by administration of carbonic anhydrase inhibitors.
- U.S. Pat. No. 5,919,813 discloses the use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy.
- U.S. Pat. No. 7,074,307 discloses electrochemical sensors for the measurement of analytes in biological fluids.
- the patent discloses the production of oxygen by an electrode in order to allow the electrochemical sensor to function at sufficient oxygen levels independent of the oxygen concentrations in the surrounding environment.
- U.S. Pat. No. 5,855,570 discloses an oxygen-producing bandage.
- the invention is a portable, self-contained device for the topical application of oxygen to promote the healing of skin wounds.
- the device includes a wound dressing that incorporates electrochemical, chemical, or thermal means for generating high purity oxygen.
- the device can regulate the supply of oxygen to an area above the wound at various concentrations, pressures and dosages.
- the device is driven by a built-in or accessory power source. Ambient air is brought into contact with a gas permeable cathode. Oxygen present in the air is reduced at the cathode to negative ions (i.e. peroxide, superoxide or hydroxyl ions) and/or their unprotonated and protonated neutral species. One or more of these species diffuse through an electrolyte and are then oxidized at a gas permeable anode to produce a high concentration of oxygen directly above the wound.
- negative ions i.e. peroxide, superoxide
- U.S. Pat. No. 4,795,423 discloses oxygenated perfluorinated perfusion of the ocular globe to treat ischemic retinopathy.
- the ocular globe is penetrated with two small cannulae and an inflow and outflow perfusion is established with an oxygenated perfluorochemical emulsion or other physiologically compatible oxygenated liquid at a rate and for a duration, sufficient to permit the natural healing process to occur.
- the treatment involves supplying oxygen to ischemic or pre-ischemic body tissue by electrolysis of body fluid proximal to or within ischemic body tissue.
- the treatment advantageously works in vitrectomized eyes as well as non-vitrectomized eyes.
- the method is based on selective and fractional electrolysis of the vitreous humor to produce oxygen, and optionally, active chlorine while simultaneously controlling pH.
- the apparatus includes a tissue-implantable electrochemical system having an anode electrode in electrical contact with a first cathode electrode.
- the electrochemical system is designed to be implantable and operable in fluid-containing biological tissue and capable of the electrolytic production of oxygen from tissue fluid proximal to or within ischemic tissue when powered by a suitable power supply.
- An object of the present invention is to treat an ischemic disease in a patient.
- Another object of the present invention is to delay or suppress the onset of diabetic retinopathy. This is accomplished by selective electrolysis of the vitreous humor and control of pH in both vitrectomized and non-vitrectomized eyes.
- the formation of free chlorine i.e., chlorinous substances other than chloride
- the above strategy can be applied to appropriate organs and tissues to treat ischemic diseases in general.
- vitreous humor can be selectively electrolyzed to produce predominantly molecular oxygen.
- the formation of free chlorine is avoided. This can be accomplished by the selection of appropriate electrolytic mono- or multi-phase pulse patterns or taking advantage of the natural antioxidant properties of the vitreous humor. Aqueous humor is continuously produced and refreshed in the eye.
- a second embodiment allows for the formation of free chlorine. Since the onset of retinopathy is believed to be a redox sensitive molecule such as cytochrome or hypoxia inducible factors, the presence of high potential free chlorine in the form of hypochlorite ions or hypochlorous acid can provide the signaling mechanism to avoid the onset of new and fragile vessel formation.
- the foregoing and other objects are achieved by mono-, bi- or multi-phasic pulsed electrolysis of water to selectively produce oxygen and avoid the formation of free chlorine.
- Selective formation of oxygen can be achieved in multiple ways.
- the electrical double layer which forms spontaneously at the surface of a metal electrode in sodium chloride solutions such as vitreous humor excludes chloride ions near the surface of the electrode.
- the water of the aqueous component of the vitreous humor can be selectively oxidized to molecular oxygen while simultaneously avoiding the oxidation of chloride ions to form free chlorine.
- the selected time profiles may be monophasic, biphasic or multiphasic.
- free chlorine is electrolytically produced to maintain an oxidizing redox potential by the ClO ⁇ /Cl ⁇ couple, which has a high oxidation potential, to provide the signaling mechanism to avoid the onset of new and fragile vessel formation.
- pH excursions that might be caused by electrolysis of a body fluid such as the vitreous humor can be corrected by use of a “pH clamp.”
- pH excursions can unfavorably alter the biochemistry of the vitreous humor.
- the pH clamp preferably uses three electrodes plus oxygen and/or pH sensors. In the case of the vitreous humor, two electrodes are preferably located in the vitreous while the third is preferably external to the ocular cavity (for example, implanted behind the ear of the patient). Information gathered by the sensors is used for selecting the operation of specific electrodes.
- the operation of specific electrodes adjusts the pH and keeps the pH within a specified range. This approach advantageously prevents pH excursions beyond ranges that may have a detrimental effect on the normal biochemistry of body fluid, such as the vitreous humor.
- the invention advantageously provides a treatment for ischemic and pre-ischemic tissues in mammals in a precise and controlled manner. In addition, the invention also achieves this without introducing chemicals into the biological tissue.
- the benefits of the invention are particularly advantageous for treatments of the eye since the eye is particularly sensitive to chemicals and invasive treatments.
- FIG. 1 is a schematic illustration of the structure of the electric double layer of a metal electrode dipping in an electrolyte solution such as sodium chloride, the primary electrolytic medium of vitreous humor. It is well known that the layer of water in immediate proximity to the metal electrode surface has a concentration of chloride ions lower than the bulk region (Butt et al., Physics and Chemistry of Interfaces , Wiley-VCH, 2003).
- FIG. 2 is an illustration of the monophasic injection of a finite amount of positive charge into an electrode to oxidize the water that is in immediate proximity to the metal surface and depleted of chloride ions.
- the injection of positive charge can be preceded by a brief injection of negative charge to further expel chloride ions away from the electrode surface. This will enlarge the chloride-depleted region.
- FIG. 3 illustrates a biphasic pulse that can be applied to reverse the formation of free chlorine.
- the free chlorine that is formed during the anodic phase can be reduced to chloride during a cathodic phase that immediately follows the anodic phase.
- FIG. 4 illustrates a cross-section of a human eye with the natural flow of fluid and production of aqueous humor.
- FIG. 5 illustrates one embodiment of the pH clamp.
- Cathode, anode, pH and oxygen sensors are located in close proximity to the region to be oxygenated.
- a second cathode is located outside the ocular cavity.
- the pH of the vitreous humor can be maintained within the desired range with this electrode configuration.
- FIG. 6 is a model glass eye-chamber that replicates the physical chemistry of electrolysis in the eye and the three-electrode pH clamp. It was used to collect the data that demonstrate that the pH clamp works.
- FIG. 7 presents data on the formation of oxygen and chlorine in phosphate buffered saline (PBS).
- the data are for 800 ⁇ A amplitude pulses with corresponding time durations presented on the abscissa. The time duration between pulses is 10 ms.
- Oxygen formation proceeds the formation of chlorine.
- FIG. 8 contains data for the simultaneous formation of hydrogen and oxygen in PBS.
- the amplitude of the pulses was 800 ⁇ A and the duration of the pulses are presented on the abscissa.
- the time duration between pulses is 10 ms.
- FIG. 9 presents a point-by-point calculation of the stoichiometric ratios of hydrogen to oxygen for the data points of FIG. 8 .
- FIG. 10 contains data on the simultaneous electrochemical formation of hydrogen and oxygen in a medium containing a synthetic chemical formulation for vitreous humor.
- the amplitude of the pulses was 800 ⁇ A and the duration of the pulses are presented on the abscissa.
- the time duration between pulses is 10 ms.
- FIG. 11 shows data for photothrombic retinal vein occlusions in rabbits.
- FIG. 12 shows results from a subgroup of rabbits which were treated with vitreous oxygenation after photothrombic vein occlusion.
- FIG. 13 shows intraretinal oxygen measurements before and after retinal artery occlusion.
- FIG. 14 shows fundus photos one week after photothrombosis in dog eyes.
- FIG. 15 shows OCT data from pre and post photothrombotic occlusion in dog retina.
- FIG. 16 shows results of short-term electrolytic oxygen production in a dog.
- FIG. 17 shows the histology from control dog eyes which underwent occlusions and received no treatment and oxygenation in dog eyes which underwent occlusion followed by vitreal oxygenation at days 3 and 7.
- FIG. 18 is a photomicrograph showing a parylene electrode array in a dog eye after six months of implantation with very little gross inflammation and no signs of infection or retinal detachment.
- FIG. 19 is a generalized schematic of the system level design for the OXYGENERATOR electrochemical system.
- FIG. 20 is a schematic showing the approximate size of the proposed implant.
- FIG. 21 is a chart showing the correlation between steady state production of O 2 or Cl 2 under repetitive pulses at 100 Hz, 800 ⁇ A amplitude and pulse duration in phosphate buffered saline.
- FIG. 22 is an illustration of the pH-control concept of the present invention.
- FIG. 23 is a chart showing pH shift during electrolysis of Ames medium plus 200 ⁇ g per ml of hyaluronic acid.
- FIG. 24 shows photos of parylene-encapsulated electrodes and coils.
- FIG. 25 illustrates an alternate view of the pH clamp as shown in FIG. 5 .
- the second cathode is located outside the ocular cavity.
- the invention is directed to a method for treating ischemic conditions or diseases in a mammal by treatment of the corresponding ischemic tissue.
- the ischemic tissue is any biological tissue suffering from lower than normal levels of oxygen, or any tissue considered predisposed or susceptible to lower levels of oxygen, i.e., pre-ischemic.
- the lower levels of oxygen are generally a result of a lower than required blood supply to specified body tissue.
- the mammal in need of treatment can be any mammal, most notably human.
- ischemic tissues examples include, but are not limited to, those associated with diabetic retinopathy in a patient's eye, retinopathy in a patient's eye caused by a retinovascular disease other than diabetes (e.g., vein and artery occlusions), retinopathy caused by choroidal ischemia (e.g., various forms of macular degeneration), ischemia in joint spaces (e.g., knee and shoulder), ischemia for cutaneous and subcutaneous spaces, ischemia in central and peripheral nervous systems (e.g., brain and spinal cord), ischemia of organs (e.g., heart, kidney, and organs of the gastrointestinal system), and ischemia on transplanted organs and tissue including stem cell transplants.
- a retinovascular disease other than diabetes e.g., vein and artery occlusions
- choroidal ischemia e.g., various forms of macular degeneration
- ischemia in joint spaces e.g., knee and shoulder
- the method involves the electrolysis of body fluid in close or intimate contact with (i.e., proximal or within) ischemic tissue to increase the oxygen levels in the ischemic tissue.
- proximal is meant an area of tissue containing biological fluid that is not necessarily within the ischemic tissue but maintains an intimate contact by exchange of biological fluid with the ischemic tissue undergoing treatment.
- Proximal tissue can also include tissue containing fluid that can act as a reservoir for higher oxygen concentrations where oxygen from the fluid can be diffused into the ischemic tissue.
- fluid includes vitreous fluid, aqueous fluid, cerebrospinal fluid, or interstitial fluid such as lymphatics.
- the electrolysis is conducted by implantation and electrical operation of an electrochemical system into the fluid of ischemic tissue.
- the implanted electrochemical system preferably includes an anode and a cathode (also referred to herein as a first anode or a first cathode).
- the cathode operating in biological fluid will primarily reduce water to hydrogen according to the following half reaction: H 2 O+2 e ⁇ ⁇ H 2 (g)+2OH ⁇ (aq)
- Superoxide anions and hydrogen peroxide can also form by cathodic reduction of dissolved oxygen. Though these species tend to be biologically toxic, the cellular enzymes superoxide dismutase and catalase are normally available for the efficient conversion of these species into non-toxic species.
- the chlorine half reaction has a higher standard potential than that of oxygen, it has a lower overpotential. Because of this, the chlorine oxidation reaction becomes significant during normal operation of the anode.
- chlorine (Cl 2 ) produced at the anode immediately reacts with water to form various hydrolysis products of chlorine.
- the predominant hydrolysis products of chlorine include HOCl (hypochlorous acid) and its ClO ⁇ salts.
- chlorine and its hydrolysis products are also referred to as “chlorinous substances.”
- production of chlorinous substances in biological fluid undergoing electrolysis is not controlled.
- This embodiment can be advantageous in certain situations where chlorinous substances are believed to have a beneficial effect.
- active chlorine can suppress or reverse the onset of diabetic retinopathy, other retinovascular diseases, and choroidal neovascularization.
- these substances can, under certain circumstances, be rendered harmless by the natural antioxidant processes of the cell. As further discussed below, this is particularly true of the vitreous humor.
- the production of chlorinous substances in biological fluid undergoing electrolysis is controlled.
- This embodiment can be advantageous in certain situations where chlorinous substances are known or believed to be toxic, inflammatory, or deleterious in some other way.
- the production of chlorinous substances can be controlled by removal of chloride ion from the vicinity of the electrodes where electrolysis is being performed. The removal of chloride ion can be accomplished by any suitable method known in the art, including chemical or physical methods.
- the production of chlorinous substances can be controlled by converting produced chlorinous substances back to chloride or to other compounds that do not possess the same adverse effects. The conversion can be accomplished by any of the means known in the art, including chemical or physical methods.
- the production of chlorinous substances is controlled by electrolytic means.
- controlled is meant that the production of chlorinous substances is lessened by any amount, including to a point where chlorinous substances are considered not present or in trace amounts that are below the threshold of adverse effects.
- the electrolytic means is a pulsed electrolytic technique capable of altering the location or concentration profile of chloride ions within an electrical double layer of the anodic electrode in such a manner that selective oxidation of water, and not chloride, is made possible.
- the pulsed electrolytic technique may be monophasic, biphasic, or multiphasic, and may include one, but more preferably, several successive pulses separated by a uniform, patterned, or variable time delay. Any suitable electrical (electrode) pulse generator can be used for generating the electrolytic pulses described herein.
- a pulsed electrolytic technique as described above can accomplish such selective oxidation of water, by, for example, applying a succession of monophasic positive pulses having a duration shorter than the kinetic relaxation time constant for reestablishing the electrical double layer of the anode.
- water is being selectively oxidized over chloride during the electrolytic pulse since chloride ion is not provided the necessary time to enter the microscopic layer of the electrical double layer containing only water.
- the pulse duration needs to be shorter than the relaxation time necessary for reestablishing the electrical double layer.
- the relaxation time varies according to electrode type, size, and chemical and physical conditions.
- a suitable pulse duration is very much dependent on the conditions encountered, and therefore, an appropriate pulse duration can vary substantially from one situation to another.
- a positive pulse is anywhere within a range having a minimum pulse time of about 50 microseconds (50 ⁇ s) and a maximum pulse of about 10 milliseconds (10 ms). More preferably, a positive pulse is within a range having a minimum pulse time of about 50 ⁇ s and a maximum pule time of about 500 ⁇ s. More preferably, the pulse duration can be in the range of about 100 to 200 ⁇ s.
- the positive pulses are separated by a suitable time delay.
- the time delay is preferably long enough for the anode to reestablish the electrical double layer.
- the time delay is preferably within a range having a minimum of about 500 ⁇ s and a maximum of about 10 ms. In other embodiments, the time delay can be in the range of about 500 ⁇ s to 5 ms or 5 ms to 10 ms.
- the water-chloride separation effect at the anode can be accentuated by preceding (preconditioning) the positive pulse with a negative pulse of adequate duration.
- the negative pulse has the primary effect of repelling chloride ions further away from the electrode surface, thereby increasing the separation of water and chloride ion at the electrode surface.
- This method provides the beneficial effect of allowing for longer positive pulse durations prior to the onset of chlorinous compound formation.
- the negative pulse has a duration preferably in the range of about 1 to 1000 ⁇ s. More preferably, the negative pulse is in the range of about 500 to 1000 ⁇ s.
- the time lapse between the negative pulse and the positive pulse is preferably in the range of about 1 to 1000 ⁇ s and more preferably about 500 to 1000 ⁇ s.
- the magnitude of the preconditioning voltage is preferably below the threshold for electrolysis.
- the production of chlorinous substances is controlled by applying a positive pulse for oxidation of water followed by a negative pulse of sufficient duration and voltage for reducing any remaining chlorinous substances to chloride ion salts.
- hypochlorite ion is converted by the negative pulse to chloride ion according to the following half reaction: 2 e ⁇ +2H + +OCl ⁇ ⁇ H 2 O+2Cl ⁇ (aq)
- the pH can be controlled by any suitable means known in the art.
- the pH is controlled by any suitable electrolytic means.
- the electrolytic means involves implanting a second cathode in biological tissue or fluid that is proximal or adjacent to the region where the first anode and first cathode have been implanted, i.e., the “pH clamp” described earlier.
- the second cathode is preferably not in electrochemical contact (i.e., not in the same electrolyte compartment) with the first anode/cathode pair.
- the second cathode is preferably external to the ocular cavity when the method is applied to ocular ischemic. See FIG. 25 . Since the formation of oxygen in water lowers the pH, inclusion of a second operational cathode, which produces hydroxide ion, will have the effect of counterbalancing the lowered pH.
- the pH of the biological fluid undergoing electrolysis can be monitored by inclusion of a suitable pH sensor in the vicinity of where electrolysis is being conducted.
- the oxygen level of the biological fluid undergoing electrolysis can be monitored by inclusion of a suitable oxygen sensor in the vicinity of where electrolysis is being conducted.
- the second cathode can be operated within an electrochemical system not part of the first anode and cathode system (i.e., as part of a separate electrochemical compartment), or alternatively, electrically connected to the first anode and cathode which have been implanted in the biological fluid of ischemic tissue.
- Feedback information from the pH and/or oxygen sensors will cause either the first anode and first cathode, or the second cathode, or both, to operate at any given time in order to adjust the pH into a desired range.
- the normal physiological range for biological tissue is in the range of about 6.5 to about 8.5. It is desirable in most cases to restrict the pH of biological tissues within this range.
- the pH can be controlled in different ways, such as by controlling the production of chlorinous substances, or controlling the production of chlorinous substances in combination with use of a second cathode, or, by sole use of a second cathode.
- the pH can be controlled so as to remain within a range of about 6.5 to about 8.5, or more preferably about 6.5 to about 8.0, or even more preferably from about 6.5 to about 7.5.
- the invention is directed to an apparatus for accomplishing the method described above.
- the apparatus includes the tissue-implantable electrochemical systems described above.
- the electrochemical system is capable of electrolytic production of oxygen from biological fluid proximal to ischemic tissue when the electrodes are implanted and made to operate by connection to a power supply source.
- connection to the power supply source need not be a physical (e.g., wired) connection.
- the connection may be, and in some instances may preferably be, in the form of a non-physical connection, such as a wireless electromagnetic transmission link between the electrochemical system and a wireless power supply source.
- a wireless transmission device the transmission of power is normally accomplished by interaction between adjacent mutually inductive devices such as coils that transfer energy by Faraday's Law of Electromagnetic Induction.
- the wireless power supply source needs to be capable of transmitting power via an electromagnetic frequency while the electrochemical system needs to be able to receive the electromagnetic transmission.
- the electromagnetic transmission can use any suitable electromagnetic frequency known in the art for transmitting power or information.
- the electromagnetic frequency used can be, for example, based on an infrared, microwave, or a radiofrequency. More preferably, the transmission is based on a radiofrequency.
- the electrochemical system can be configured, if desired, to store the power transmitted for later use.
- Examples of physically-connected power supplies that can be used to drive electrolysis in connection with the present invention include conventional batteries, fuel cells, biological fuel cells or bio-batteries or batteries powered by biomotion, and solar power devices.
- Electrodes for medical applications are well known (see e.g., J. Weiland, W. Liu and M. S. Humayun, “Retinal Prosthesis,” Ann. Rev. Biomed. Eng. 7, 361-401 (2005)). Any of the electrodes known in the art that are suitable for implantation into biological tissue are considered suitable for the present invention.
- the electrodes can be of any suitable size, shape, and construction that permit them to be implanted and non-injurious to the subject under treatment.
- the electrodes are spherical in shape and constructed of platinum.
- the size of the electrodes is preferably within the range of about 0.1 to 10 mm, and more preferably, particularly for use in the eye, in the range of about 0.5 to 2 mm, and even more preferably about 1 mm. It is well known that the functional surface area of electrodes and catalysts can be made much larger than the apparent geometrical area. These techniques will be advantageously employed in this invention.
- the distance between the first anode and cathode is preferably in a range of about 20 to 80 microns. More preferably, the distance between electrodes is about 30 to 70 microns, such as, for example, 50 microns.
- FIG. 1 is an illustration of the structure of the electric double layer at the metal electrolyte interface.
- the aqueous region 10 immediately surrounding electrode 12 has a lower chloride ion concentration than that of the bulk aqueous phase 16 .
- the concentration of chloride ions increases with distance from the electrode surface until it reaches the bulk value.
- Chloride ion concentration at the outer Helmholtz plane 14 has an intermediate value.
- FIG. 2 illustrates the injection of positive charge 10 into the electrode. If the duration 12 of the pulse is less than the characteristic kinetic time constant for the movement of chloride ions to the surface of the electrode, water will be primarily oxidized to molecular oxygen at the anode while avoiding excessive formation of free chlorine. This is illustrated by the first equation 16 of FIG. 2 , 2H 2 O ⁇ O 2 +4H + +4e ⁇ . Chlorine gas, if formed, immediately reacts with water to form hypochlorite ions and hypochlorous acid.
- repetitive pulses can be used to preferentially produce oxygen instead of chlorine by waiting a period of time equal to or greater than the relaxation time required to reestablish the electric double layer structure.
- the data of FIG. 7 provides experimental proof of this aspect of the invention. Whereas oxygen is formed at pulse durations of 100 to 200 ⁇ s, no detectable chlorine is formed into this range of pulse durations. The onset of chlorine formation by the oxidation of chloride ions at the anode/electrolyte interface is kinetically slower than the onset of oxygen formation by the electrochemical oxidation of water.
- the data of FIG. 8 contains the simultaneous electrochemical formation of oxygen and hydrogen by the pulsed electrolysis of PBS. The oxygen data is the same as that presented in FIG. 7 .
- FIG. 9 contains the corresponding stoichiometric ratios of hydrogen to oxygen in PBS. The ratio approaches two as the absolute amount of injected charge saturates the capacitance of the interfacial double layer.
- the preferential formation of oxygen over free chlorine can be enhanced by a preparatory injection of negative charge immediately followed by the injection of Faradaic positive charge for the production of oxygen.
- the formation of a higher absolute value of negative potential will contribute to the further depletion of chloride ions in the immediate proximity of the metal electrolyte interface. This will have the beneficial effect of lengthening the allowable pulse duration prior to the onset of free chlorine formation.
- FIG. 3 Another method to reduce the formation of free chlorine is illustrated in FIG. 3 .
- unwanted hypochlorite ions may form as illustrated by reactions 18 .
- An immediate negative reversal pulse 14 for duration 16 will reduce the hypochlorite/hypochlorous acid back to chloride ions, illustrated by reaction 20 , 2e ⁇ +2H + +OCl ⁇ ⁇ H 2 O+Cl ⁇ .
- Vitreous humor has the following composition: water, collagen fibrils, sugar, ascorbic acid, hyaluronic acid and inorganic salts, mostly sodium chloride.
- Sugar and ascorbic acid are good antioxidants in the context of reacting with free chlorine. Moreover, they are also good antioxidants for reacting with superoxide anions and hydrogen peroxide that may form at the cathode (in addition to the action of the superoxide dismutase and catalase, mentioned above).
- Vitreous humor has a glucose concentration of 3.4 mM and an ascorbic acid concentration of 2.0 mM. Also, as illustrated in FIG. 4 , aqueous humor 10 is naturally produced in the eye 12 at a rate of 2-3 ⁇ L per minute. Therefore, there is a steady-state supply 14 of both glucose and ascorbic acid.
- aqueous humor 10 is naturally produced in the eye 12 at a rate of 2-3 ⁇ L per minute. Therefore, there is a steady-state supply 14 of both glucose and ascorbic acid.
- FIG. 10 presents data on the simultaneous electrochemical formation of hydrogen and oxygen in a synthetic medium of vitreous humor. Under these conditions chlorine formation at the anode is quickly eliminated by its rapid reaction with ascorbate and its somewhat slower rate of reaction with glucose.
- the two anodic reactions are H 2 O (liquid) ⁇ 1 ⁇ 2O 2 (gas)+2H + (aq)+2e ⁇ and 2Cl ⁇ (aq) ⁇ Cl 2 (gas)+2e ⁇ .
- the major cathode reaction is 2H 2 O (liquid)+2e ⁇ ⁇ H 2 (gas)+2OH ⁇ .
- the exclusive formation of hydrogen and oxygen produce compensating amounts of hydrogen ions and do not alter the pH.
- the oxidation of chloride ions to produce free chlorine does not involve hydrogen ion formation. Therefore, pH drift can occur.
- the solution to pH drift is to use the pH clamp illustrated in FIG. 5 (or as alternately shown in FIG.
- the pH clamp is comprised of two intraocular electrodes 10 and 12 along with pH and O 2 sensors 14 and 16 .
- oxygen sensor signals the onset of ischemia of retinal and choroidal tissue electrolytic production of oxygen/free chlorine (and hydrogen) may proceed.
- a third electrode 18 that is employed as an alternate cathode is also present.
- FIG. 6 a model eye chamber that provides proof of principle for the pH clamp concept.
- FIG. 6 contains the chemical mixture that represents the vitreous humor.
- 10 is a pH probe.
- Two electrodes numbered 14 are in the “ocular cavity” whereas a third electrode (second cathode) 16 is located outside the cavity (“behind the ear”) and separated by a fine frit in a tubular pathway that is filled with synthetic vitreous.
- the following tables contain experimental data for pH as a function of time for two electrode configurations:
- the hydrogen-evolving cathode consumes hydrogen ions on a stoichiometric basis that exceeds the hydrogen ion production via the oxygen reaction by the equivalent amount of chloride ions that are oxidized.
- Rabbits were initially used instead of dogs to establish the methodology to measure oxygen because of the lack of inner retinal blood flow and large pre-retinal oxygen tension gradients that exist over vascularized medullary wings and avascular retina. This allows for easy calibration of the oxygen probes. Moreover, vein occlusions lead to profound retinal ischemia making oxygen measurements easy. Briefly, pigmented rabbits underwent fluorescein angiograms (FA), color fundus photos, and optical coherence tomography (OCT), and vitreous samples for VEGF at baseline and then occlusions were created photothrombotically in the right eye. Following this, the animals were divided into three experimental groups; Control, Sham and Oxygenation.
- FA fluorescein angiograms
- OCT optical coherence tomography
- Oxygen measurements were taken at multiple points (in the mid-vitreous as well as pre-retinal) at baseline and following occlusion using a fiberoptic oxygen sensitive probe (Oxford Optronix) This system based on fluorescence quenching has a range from 0 to 100 mmHg O 2 and has been used previously for intraocular oxygen recordings in human. Measurements were recorded in each position for a minimum of 30 seconds or until the reading stabilized.
- retinal vein occlusions were performed in four rabbits. Data shown is from baseline (preocclusion), and three days after photothrombotic occlusion. Standard deviations are in parentheses. Intraocular oxygen recordings taken at different positions in the vitreous demonstrated marked reduction in oxygen levels after occlusion. OCT recordings demonstrated increased retinal thickness consistent with the edema seen on clinical exam. Vitreous samples analyzed for VEGF showed large increases in the VEGF levels in the post-occlusion state.
- FIG. 12 shows results from a subgroup of rabbits which were treated with vitreous oxygenation after photothrombotic vein occlusion.
- 10 A Oxygen recordings taken 7 days following occlusion, before and immediately after one hour of oxygen delivery to the vitreous at the rate of 6 ⁇ L O2/min. Oxygen levels over the retina were considerably higher than the very low oxygen levels seen in animals with RVO before oxygenation (i.e., baseline recordings). P values are shown in parentheses.
- 10 B The percent increase in vitreous VEGF levels relative to pre-occlusion levels, at 7 days after occlusion. Treated animals were given one hour of oxygenation 3 days following occlusion. Oxygenated animals had a lesser degree of upregulation of VEGF within the vitreous. Note that because only one hour of oxygen was administered, VEGF levels were not expected to normalize.
- FIG. 13A shows markedly reduced levels of intraretinal oxygen after retinal artery occlusion.
- FIG. 13B shows increased pre-retinal oxygen levels as well as increased oxygenation in the retina especially to the inner retina after retinal artery occlusion and after increasing the oxygen in the vitreous.
- FIGS. 14 and 15 show the result of the procedure for inducing RVO's in dogs (see FIGS. 14 , 15 ).
- photos A and B show fundus photos one week after photothrombosis in dogs.
- the photos show dilated and tortuous retinal vessels, intraretinal hemorrhage and edma.
- Fluorescein angiography photos C and D show similar findings as well as the site of occlusion surrounded by leakage of dye (see arrow in D).
- FIG. 15 shows OCT data from pre and post photothrombic occlusion in dog retina.
- Photo A shows an OCT image from an area of canine retina located inferiorly outside of the tapetum prior to occlusion.
- Photo B shows an OCT image from the same area of the retina four days following occlusion shows marked retinal edema, cystic changes within the retina (white arrow) as well as serous retinal detachment (red arrow). Images are each 2 mm ⁇ 5 mm.
- FIG. 16 shows the results of short-term electrolytic oxygen production in one dog.
- Oxygen recordings were taken in a preretinal location over normal retina and over retina that had undergone photothrombotic vein occlusion both before and after one hour of electrolytic oxygenation.
- a drop in pre-retinal oxygen levels with occlusion is demonstrated as well as the restoration of pre-retinal oxygen levels after one hour of electrolytic oxygen production.
- Bubble evolution was not visible and pH recordings always remained stable at 7.5.
- intraocular oxygen recording were taken before and after one hour of electrolytic oxygen production within the vitreous.
- the electrolysis was carried out with two 1 mm sphere platinum electrodes surgically introduced via the pars plan and positioned in the anterior vitreous and stimulated with 800 ⁇ A monophasic pulses of 200 ⁇ s duration with a 1000 ⁇ s delay. A marked elevation of the oxygen gradients within the vitreous was observed (see FIG. 16 ). In order to extend the electrode metal half-life, biphasic pulses are also being studied.
- histological analysis revealed no difference between control dog eyes with RVO's and the intermittently oxygenation treated eyes. This can be considered an encouraging result as delivering oxygen through the vitreous did not result in increased toxicity to the retina. As for observing a protective effect, there was not expected to be a beneficial response because the oxygenation was intermittent and only delivered twice for one hour each time over the 14 day period after RVO.
- FIG. 18 is a photomicrograph showing a parlyene electrode array in a dog eye after six months of implantation with very little gross inflammation and no signs of infection or retinal detachment.
- the arrow shows the site where the electrode array is transscleral.
- the intraocular electrode array ends just inside the eye wall and not need to be tacked onto the retina as shown here.
- An implantable device has been designed which raises dissolved O2 levels in the eye by select electrolysis of the intraocular fluid. Besides producing oxygen, sensors are used to monitor physiologically important parameters such as the dissolved oxygen levels and pH. The electrolysis circuit is under the feedback control of the sensors. RF coils are used to transfer power and data between the implanted device and external (wearable/portable) electronics.
- FIG. 19 shows a block diagram of the system.
- the implanted part of the device not only has the telemetry receiving coil and the microelectronic circuitry to receive this radio frequency (RF) data and power link but also the ability to receive input from sensing electrodes and drive current through electrolysis electrodes.
- the second cathode electrode (third electrode) used for pH clamping is not shown.
- the external unit includes a transmitting coil, electronics, and battery. (not shown) that will activate the implanted unit.
- This wireless (e.g., radio frequency, RF) controller can be used during day or night. At night, it is possible for the transmitter coil to be in the pillow.
- the main electrolysis components except the application specific integrated chipset (ASIC) have been prototyped with microelectromechanical systems (MEMS) engineering using parylene, a biomaterial with the highest possible FDA biocompatibility rating i.e, class VI FDA biomaterial.
- MEMS microelectromechanical systems
- an effective surface area can be obtained that exceeds the actual electrode area by 50 ⁇ . This increases the efficiency of electrolysis hence requiring less power to produce more O 2 per apparent geometric area.
- pH fluctuations can be prevented.
- the total power consumption for the entire device including the discrete components for the inductive (RF) link, as well as ASIC and the cantilever sensors is less than 10 mW, which will result in no observable temperature increase in the tissue.
- RF inductive
- This implanted receiver coil with an outer diameter of 10 mm and an inner diameter of 3 mm operating at a frequency of 2 MHz is capable of wirelessly transmitting the needed power levels.
- the ASIC design also uses standard CMOS process that makes it easy to fabricate.
- the coil combined with the ASIC, limited number of discrete electronic components, and electrolysis electrodes creates a compact and flexible package suitable for long-term implantation.
- the incision in the eye wall to introduce the foldable electrodes would be less than 1 mm in diameter and the rest of the device on a flexible substrate with a soft polymer consistency can be easily sutured to the eye wall under the conjunctiva limiting the risk of exposure.
- a diagram showing the approximate size of the implant is shown in FIG. 20 .
- FIG. 21 contains kinetic data for 0.85 mm platinum diameter electrodes with PBS and demonstrates the kinetic time course for the onset of oxygen and chlorine evolution.
- PBS a buffered 0.15 M NaCl solution
- chloride anions are largely excluded from the inner and outer Helmholtz planes, the regions of the electrolyte that are immediately adjacent to the electrode.
- Each data point represents the steady-state production of oxygen or chlorine for 100 Hz repetitive anodic pulses of 800 ⁇ A and 0-400 ⁇ s pulse duration.
- the onset of chlorine production occurs at a 200 ⁇ s pulse width. That is to say, sufficiently rapid injection of positive charge into the anode can complete the oxidation of water to molecular oxygen prior to the movement of bulk chloride ions to the electrode surface where the Cl ⁇ is oxidized to chlorine.
- Oxygen and the coevolved hydrogen were detected in the gas phase using flow comprised of an electrogalvanic cell for the oxygen sensor and a tin oxide semiconductor for the hydrogen sensor.
- the production of free chlorine was detected in a standard spectrophotometric assay based on the rapid and quantitative oxidation of ascorbic acid.
- FIG. 21 is an original discovery associated with this proposal which shows that the structure of the electric double layer can be used to selectively oxygenate tissue in chloride ion containing fluids without the corresponding electrolytic formation of free chlorine. Interestingly, this is the inverse goal of the chlor-alkali process, one of the oldest industrial processes, in which the aim is to maximize the production of chlorine by the electrolysis of brine. It may also be possible to extend the half-life of the platinum electrodes by use of charge-balanced symmetric and asymmetric biphasic current pulses.
- the pH Clamp Although vitreous humor is primarily physiological saline, it contains other components such as hyaluronic acid, glucose, ascorbate, collagen fibrils, etc. Even if chlorine formation was completely suppressed, the pH may still drift. Accordingly, a pH clamp, as specially designed for the present invention, can be used.
- the pH clamp uses a three electrode configuration to maintain constant pH under all conditions of oxygenation of the vitreous.
- FIGS. 22 and 23 illustrate the idea.
- the anode is the source of oxygen.
- the cathode is the source of hydrogen. Two cathodes are illustrated. One cathode is in the intraocular cavity, adjacent to the anode.
- the other cathode is located outside the ocular cavity, but is electrically connected to it via the ionic conductivity of the tissue.
- Which pair of electrodes is used for the electrolysis is determined by the pH sensor and the electronic feedback switching circuit that selects the electrodes.
- a photograph of the experimental chamber is presented in the inset in FIG. 22 .
- the data of FIG. 23 represent electrolysis of 800 ⁇ A for one hour of Ames medium+200 ⁇ g per ml hyaluronic acid. Note that the starting pH of this solution was 7.4 and that, while using the internal electrodes, there is a slight increase in the pH which in the eye should be buffered by the vitreous.
- the cantilevered pH sensors would detect this and switch the device into a mode of using the extraocular electrode.
- the pH With the cathode external to the vitreous cavity, the pH becomes acidic. This is because the oxidation of water generates four moles of protons per mole of oxygen, 2H2O ⁇ O2+4H + +4e ⁇ .
- the external electrode By selecting the external electrode, the pH can be reduced, thereby restoring the pH to its original value. It is this ability to alternately select the appropriate pair of electrodes that provides constant pH control inside the eye.
- Oxygen and hydrogen evolution are by far the major electrolytic reactions at the anode and cathode.
- the objective of the repetitive pulsing strategy is to suppress formation of free chlorine, Cl 2 .
- Cl 2 free chlorine
- hypochlorite ions OCl ⁇
- hypochlorous acid HOCl which has a pKa of 7.53.
- Electrolytic formation of molecular hydrogen, H 2 can be ignored. It is unreactive under experimental conditions in the eye.
- the inset in FIG. 22 illustrates minor pathways that can potentially form superoxide anions, O 2 ⁇ , and hydrogen peroxide, H 2 O 2 .
- these species are normally efficiently eliminated by the natural superoxide dismutase and catalase activity in the vitreous.
- ascorbate and glucose which have antioxidant activity, are present at millimolar concentrations in the vitreous.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Radiology & Medical Imaging (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
H2O+2e −→H2(g)+2OH−(aq)
H2O→½O2(g)+2H+(aq)+2e − (E0 at 25° C.=1.23 Volts vs NHE)
2Cl−→Cl2(g)+2e − (E0 at 25° C.=1.36 Volts vs NHE)
2e −+2H++OCl−→H2O+2Cl−(aq)
TABLE 1 |
1 mA DC, Anode in the cell chamber and cathode in the side arm. |
Time (hr) | |
||
0 | 7.9 | ||
1 | 2.6 | ||
2 | 1.9 | ||
3 | 1.9 | ||
TABLE 2 |
1 mA DC, Cathode and anode in the cell chamber |
Time (hr) | |
||
0 | 7.7 | ||
1 | 8.1 | ||
2 | 9.1 | ||
3 | 9.3 | ||
4.75 | 9.4 | ||
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/523,990 US8209024B2 (en) | 2007-01-22 | 2008-01-22 | Method and apparatus for treating ischemic diseases |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88595807P | 2007-01-22 | 2007-01-22 | |
US12/523,990 US8209024B2 (en) | 2007-01-22 | 2008-01-22 | Method and apparatus for treating ischemic diseases |
PCT/US2008/000742 WO2008091559A1 (en) | 2007-01-22 | 2008-01-22 | Method and apparatus for treating ischemic diseases |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/000742 A-371-Of-International WO2008091559A1 (en) | 2007-01-22 | 2008-01-22 | Method and apparatus for treating ischemic diseases |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/488,302 Continuation US8655452B2 (en) | 2007-01-22 | 2012-06-04 | Method and apparatus for treating ischemic diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
US20100168646A1 US20100168646A1 (en) | 2010-07-01 |
US8209024B2 true US8209024B2 (en) | 2012-06-26 |
Family
ID=39644787
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/523,990 Active 2028-08-15 US8209024B2 (en) | 2007-01-22 | 2008-01-22 | Method and apparatus for treating ischemic diseases |
US13/488,302 Expired - Fee Related US8655452B2 (en) | 2007-01-22 | 2012-06-04 | Method and apparatus for treating ischemic diseases |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/488,302 Expired - Fee Related US8655452B2 (en) | 2007-01-22 | 2012-06-04 | Method and apparatus for treating ischemic diseases |
Country Status (4)
Country | Link |
---|---|
US (2) | US8209024B2 (en) |
EP (1) | EP2111250B1 (en) |
JP (2) | JP2010516389A (en) |
WO (1) | WO2008091559A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130106347A1 (en) * | 2011-10-28 | 2013-05-02 | Medtronic, Inc. | Heat management for recharge coils for implantable medical devices |
US8655452B2 (en) | 2007-01-22 | 2014-02-18 | Ut-Battelle, Llc | Method and apparatus for treating ischemic diseases |
EP2903573A4 (en) * | 2012-10-05 | 2016-06-01 | Univ Southern California | Implantable oxygenator with self-contained electrolyte |
US9560787B2 (en) | 2011-10-28 | 2017-01-31 | Medtronic, Inc. | Removable heat management for recharge coils |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9056201B1 (en) | 2008-01-07 | 2015-06-16 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive delivery of radiation to the eye |
US8608632B1 (en) | 2009-07-03 | 2013-12-17 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive extraocular delivery of radiation and/or pharmaceutics to the posterior portion of the eye |
US9873001B2 (en) | 2008-01-07 | 2018-01-23 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive delivery of radiation to the eye |
US10022558B1 (en) | 2008-01-07 | 2018-07-17 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive delivery of radiation to the eye |
EP2676701B1 (en) | 2008-01-07 | 2016-03-30 | Salutaris Medical Devices, Inc. | Devices for minimally-invasive extraocular delivery of radiation to the posterior portion of the eye |
US8602959B1 (en) | 2010-05-21 | 2013-12-10 | Robert Park | Methods and devices for delivery of radiation to the posterior portion of the eye |
USD691270S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to an eye |
USD691269S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to an eye |
USD691268S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to eye |
USD691267S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to eye |
CA2751454C (en) * | 2009-02-03 | 2013-08-06 | Purdue Research Foundation | Method and apparatus for improving local hypoxicity for enhanced therapy |
EP3068327B8 (en) | 2013-11-14 | 2022-02-23 | RM2 Technology LLC | Systems, and apparatuses for tissue ablation using electrolysis and permeabilization |
CN108472071B (en) | 2015-05-01 | 2021-03-16 | 因特科学股份有限公司 | Methods, systems, and apparatus for tissue ablation using pulse shape design |
US20160367831A1 (en) * | 2015-06-17 | 2016-12-22 | Chang Gung Memorial Hospital, Linkou | Implantable medical device, system and method for inducing thrombosis in an artery of a living animal |
CN108024852B (en) * | 2015-09-11 | 2019-11-08 | 加州理工学院 | Implantable oxygen generator and conveyer |
USD815285S1 (en) | 2016-05-11 | 2018-04-10 | Salutaris Medical Devices, Inc. | Brachytherapy device |
USD814637S1 (en) | 2016-05-11 | 2018-04-03 | Salutaris Medical Devices, Inc. | Brachytherapy device |
USD814638S1 (en) | 2016-05-11 | 2018-04-03 | Salutaris Medical Devices, Inc. | Brachytherapy device |
USD808529S1 (en) | 2016-08-31 | 2018-01-23 | Salutaris Medical Devices, Inc. | Holder for a brachytherapy device |
USD808528S1 (en) | 2016-08-31 | 2018-01-23 | Salutaris Medical Devices, Inc. | Holder for a brachytherapy device |
US10492945B2 (en) | 2017-05-22 | 2019-12-03 | California Institute Of Technology | Small molecule transport device with anti-condensation filler for drug delivery or waste removal |
AU2020253445A1 (en) * | 2019-04-01 | 2021-11-25 | Judith Boston | Treatment of ischemic conditions, hypoxic conditions, conditions related to a hypoxia-induction factor |
US20220183880A1 (en) * | 2019-04-02 | 2022-06-16 | The Regents Of The University Of California | Method and apparatus to modify the cornea using electrochemistry |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4180445A (en) | 1978-03-27 | 1979-12-25 | Diamond Shamrock Corporation | Oxygen selective anode |
US5213570A (en) | 1990-12-14 | 1993-05-25 | Mallinckrodt Medical, Inc. | System and method for oxygenation of the pericardium |
US6901296B1 (en) | 2001-05-25 | 2005-05-31 | Advanced Bionics Corporation | Methods and systems for direct electrical current stimulation as a therapy for cancer and other neoplastic diseases |
US6902564B2 (en) | 2001-08-15 | 2005-06-07 | Roy E. Morgan | Methods and devices for electrosurgery |
US20060217783A1 (en) | 2004-02-06 | 2006-09-28 | Harold Thomas W | Treatment of vision disorders using electrical, light, and/or sound energy |
US20080116064A1 (en) | 2006-05-09 | 2008-05-22 | Daiki Ataka Engineering Co., Ltd. | Oxygen evolution electrode |
US7813807B2 (en) * | 2006-08-15 | 2010-10-12 | Oxyband Technologies, Inc. | Systems and methods for treatment of retinopathy and other eye diseases |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5578022A (en) * | 1995-04-12 | 1996-11-26 | Scherson; Daniel A. | Oxygen producing bandage and method |
US20020188323A1 (en) * | 2001-03-19 | 2002-12-12 | Remon Medical Technologies Ltd. | Methods, systems and devices for in vivo electrochemical production of therapeutic agents |
EP1515775A4 (en) * | 2002-05-07 | 2010-03-03 | Oncostim Inc | Method and device for treating concer with electrical therapy in conjunction with chemotherapeutic agents and radiation therapy |
AU2004320509A1 (en) * | 2004-06-02 | 2005-12-22 | Darrel Dean Drinan | Use of electric fields to minimize rejection of implanted devices and materials |
WO2008091559A1 (en) | 2007-01-22 | 2008-07-31 | Elias Greenbaum | Method and apparatus for treating ischemic diseases |
-
2008
- 2008-01-22 WO PCT/US2008/000742 patent/WO2008091559A1/en active Application Filing
- 2008-01-22 US US12/523,990 patent/US8209024B2/en active Active
- 2008-01-22 EP EP08713191.8A patent/EP2111250B1/en not_active Not-in-force
- 2008-01-22 JP JP2009547267A patent/JP2010516389A/en active Pending
-
2012
- 2012-06-04 US US13/488,302 patent/US8655452B2/en not_active Expired - Fee Related
-
2013
- 2013-01-17 JP JP2013006536A patent/JP2013126551A/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4180445A (en) | 1978-03-27 | 1979-12-25 | Diamond Shamrock Corporation | Oxygen selective anode |
US5213570A (en) | 1990-12-14 | 1993-05-25 | Mallinckrodt Medical, Inc. | System and method for oxygenation of the pericardium |
US6901296B1 (en) | 2001-05-25 | 2005-05-31 | Advanced Bionics Corporation | Methods and systems for direct electrical current stimulation as a therapy for cancer and other neoplastic diseases |
US6902564B2 (en) | 2001-08-15 | 2005-06-07 | Roy E. Morgan | Methods and devices for electrosurgery |
US20060217783A1 (en) | 2004-02-06 | 2006-09-28 | Harold Thomas W | Treatment of vision disorders using electrical, light, and/or sound energy |
US20080116064A1 (en) | 2006-05-09 | 2008-05-22 | Daiki Ataka Engineering Co., Ltd. | Oxygen evolution electrode |
US7813807B2 (en) * | 2006-08-15 | 2010-10-12 | Oxyband Technologies, Inc. | Systems and methods for treatment of retinopathy and other eye diseases |
Non-Patent Citations (7)
Title |
---|
Abdel Ghany et al. Oxygen evolution anodes composed of anodically deposited Mn-Mo-Fe oxides for seawater electrolysis. Electrochimica Acta 48 (2002) pp. 21-28. |
Ahmed J. et al., "Oxygen distribution in the macaque retina," Investigative Opthalmology & Visual Science, vol. 34 (3), pp. 516-521 (Mar. 1993). |
Bennett, J.E. Electrodes for Generation of Hydrogen and Oxygen from Seawater. Int. J. Hydrogen Energy, vol. 5, pp. 401-408. Pergamon Press Ltd. 1980. |
Conway B.E. et al., "Kinetic and optical relaxation studies of adsorbed intermediate in some electrochemical reactions," Faraday Discuss. Chem. Soc. vol. 56, pp. 210-227 (1973). Abstract only. |
Extended European Search Report, dated Dec. 28, 2011, for European Application No. 08713191.8-1269, entitled "Method and Apparatus for Treating Ischemic Diseases," based on PCT Application No. PCT/US2008/000742, published Jul. 31, 2008, as WO/2008/091559. |
International Search Report and Written Opinion of the International Searching Authority, mailed May 19, 2008, for PCT Application No. PCT/US2008/000742. |
Song, et al. Preparation and Characterization of Manganese Dioxide Electrodes for Highly Selective Oxygen Evolution During Diluted Chloride Solution Electrolysis. J. Ind. Eng. Chem., vol. 13, No. 4, (2007) pp. 545-551. |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8655452B2 (en) | 2007-01-22 | 2014-02-18 | Ut-Battelle, Llc | Method and apparatus for treating ischemic diseases |
US20130106347A1 (en) * | 2011-10-28 | 2013-05-02 | Medtronic, Inc. | Heat management for recharge coils for implantable medical devices |
US9560787B2 (en) | 2011-10-28 | 2017-01-31 | Medtronic, Inc. | Removable heat management for recharge coils |
US10322288B2 (en) * | 2011-10-28 | 2019-06-18 | Medtronic, Inc. | Heat management for recharge coils for implantable medical devices |
EP2903573A4 (en) * | 2012-10-05 | 2016-06-01 | Univ Southern California | Implantable oxygenator with self-contained electrolyte |
US9919140B2 (en) | 2012-10-05 | 2018-03-20 | University Of Southern California | Implantable oxygenator with self-contained electrolyte |
Also Published As
Publication number | Publication date |
---|---|
US8655452B2 (en) | 2014-02-18 |
WO2008091559A1 (en) | 2008-07-31 |
EP2111250A1 (en) | 2009-10-28 |
JP2013126551A (en) | 2013-06-27 |
US20130023959A1 (en) | 2013-01-24 |
JP2010516389A (en) | 2010-05-20 |
EP2111250B1 (en) | 2017-10-04 |
US20100168646A1 (en) | 2010-07-01 |
EP2111250A4 (en) | 2012-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8209024B2 (en) | Method and apparatus for treating ischemic diseases | |
US7813807B2 (en) | Systems and methods for treatment of retinopathy and other eye diseases | |
US20220105256A1 (en) | Methods, systems, and apparatuses for delivery of electrolysis products | |
EP2121123B1 (en) | Renal function modulation via electrical energy stimulation | |
US9339653B2 (en) | Electrical stimulation treatment of hypotension | |
US8419716B2 (en) | Tissue stimulating device and method | |
JP6335904B2 (en) | Oxygen supply | |
US20140249395A1 (en) | Implantable Electrochemical Biosensors for Retinal Prostheses | |
US11826572B2 (en) | Nerve block by electrical pulses at sub-threshold intensity | |
JP2016532490A (en) | Therapeutic electron and ion transfer through a half-cell | |
US10232043B2 (en) | Photoactivated molecules for light-induced modulation of the activity of electrically excitable cells and methods of using the same | |
EP3027229B1 (en) | Photoactivated molecules for light-induced modulation of the activity of electrically excitable cells and methods of using same | |
JPH06327777A (en) | Electrical chemical introducing device | |
Rao | Electrochemical methodologies in biomedical applications | |
RU2510254C1 (en) | Method for postoperative rehabilitation of patients suffering glaucoma | |
EP0616818A2 (en) | Electrical, drug introducing apparatus | |
Greenbaum et al. | Metabolic prosthesis may help oxygenate deprived eye tissue | |
Brunton et al. | Report on Physiology |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: UNIVERSITY OF SOUTHERN CALIFORNIA,CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HUMAYUN, MARK S.;REEL/FRAME:024309/0922 Effective date: 20100325 Owner name: UT-BATTELLE, LLC,TENNESSEE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GREENBAUM, ELIAS;REEL/FRAME:024309/0969 Effective date: 20080122 Owner name: UNIVERSITY OF SOUTHERN CALIFORNIA, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HUMAYUN, MARK S.;REEL/FRAME:024309/0922 Effective date: 20100325 Owner name: UT-BATTELLE, LLC, TENNESSEE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GREENBAUM, ELIAS;REEL/FRAME:024309/0969 Effective date: 20080122 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
CC | Certificate of correction | ||
FPAY | Fee payment |
Year of fee payment: 4 |
|
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FEPP | Fee payment procedure |
Free format text: 7.5 YR SURCHARGE - LATE PMT W/IN 6 MO, LARGE ENTITY (ORIGINAL EVENT CODE: M1555); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 8 |
|
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |